Knee Osteoarthritis is a major clinical and economic burden to payors in the US
- MSK conditions have a $380 billion annual health burden equaling ~9% of total healthcare costs48
- 64 Million MSK patients report limitations in performing activities of daily living (ADL)49
- Recommended by NICE for people with severe knee osteoarthritis51
Payors will typically spend over $21,000,000 per 100,000 members on Knee Osteoarthritis in patients > 6552
Surgery
Radiology
Injections
Apos® provides an opportunity to cut costs as 84% of patients did not progress to Total Knee Replacement surgery over a 2-year time period.50
Meet Apos®
An innovative FDA-cleared47 medical device to improve clinical outcomes and reduce spending related to knee osteoarthritis also recommended by NICE.
- 86% reduction in TKR over 2 years50
- 83% of patients report a greater than 50% in pain reduction42
Treating the underlying problem changes everything.
Apos® is a non-invasive medical device that is personalized to treat the cause of your specific pain by retraining your gait (how you walk) to help you move better and live better.
Redistribute:
Shift your weight away from painful areas42
Reeducate:
Retrain how you walk for long-term relief even when not wearing your Apos®42
Delivering on triple aim for payors
David Nash, MD, MBA
Founding Dean Emeritus at Jefferson College of Population Health
“AposHealth provided us a compelling clinical and economical value proposition by offering a non-invasive alternative to knee replacement surgery for our members”
Bruce Nash, MD, MBA
Former Chief Physician Executive Blue Cross Blue Shield of Massachusetts
“Osteoarthritis of the knee and back are growing population health problems. Apos achieves the Triple Aim by reducing cost, improving health, and improving the patient experience.”
